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Background: Consumption of a cholesterol lowering dietary portfolio including plant sterols (PS), viscous fibre, soy
proteins and nuts for 6 months improves blood lipid profile. Plant sterols reduce blood cholesterol by inhibiting
intestinal cholesterol absorption and concerns have been raised whether PS consumption reduces fat soluble
vitamin absorption.
Objective: The objective was to determine effects of consumption of a cholesterol lowering dietary portfolio on
circulating concentrations of PS and fat soluble vitamins.
Methods: Using a parallel design study, 351 hyperlipidemic participants from 4 centres across Canada were
randomized to 1 of 3 groups. Participants followed dietary advice with control or portfolio diet. Participants on
routine and intensive portfolio involved 2 and 7 clinic visits, respectively, over 6 months.
Results: No changes in plasma concentrations of α and γ tocopherol, lutein, lycopene and retinol, but decreased
β-carotene concentrations were observed with intensive (week 12:p = 0.045; week 24:p = 0.039) and routine (week
12:p = 0.031; week 24:p = 0.078) portfolio groups compared to control. However, cholesterol adjusted β-carotene
and fat soluble compound concentrations were not different compared to control. Plasma PS concentrations were
increased with intensive (campesterol:p = 0.012; β-sitosterol:p = 0.035) and routine (campesterol: p = 0.034; β-sitosterol:
p = 0.080) portfolio groups compared to control. Plasma cholesterol-adjusted campesterol and β-sitosterol
concentrations were negatively correlated (p < 0.001) with total and LDL-C levels.
Conclusion: Results demonstrate that consuming a portfolio diet reduces serum total and LDL-C levels while
increasing PS values, without altering fat soluble compounds concentrations. The extent of increments of PS with
the current study are not deleterious and also maintaining optimum levels of fat soluble vitamins are of paramount
necessity to maintain overall metabolism and health. Results indicate portfolio diet as one of the best options for CVD
risk reduction.
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Randomized control trials using metabolically controlled
designs [1-3] as well as effectiveness trials with free
living designs [4,5] have demonstrated reductions in
blood LDL-C concentrations with consumption of a
portfolio diet including plant sterols (PS), soy proteins,
viscous fibres and nuts. Consumption of portfolio diet
for 1 year under real world conditions by 66 participants
resulted in a 13% reduction in LDL-C levels [5]. Similarly,
a recently conducted study with portfolio diet for 6 months
using a multicentre design across Canada showed a 13.8%
reduction in LDL-C in 330 participants [4].
Plant sterols are one of the components of the portfo-
lio diet known for their plasma cholesterol reducing
property. Consumption of 2 g/d of PS reduces LDL-C by
13 to 16% [6]. PS are found to be effectively beneficial
when combined with different dietary components such
as fish oil, ascorbic acid, β-glucan and psyllium [7-9] as
well as with statin drugs [10,11]. Consumption of PS
might not cause any major health concern [12], although
some studies have implicated increased PS concentrations
in plasma as being associated with elevated cardiovascular
disease (CVD) risk [13-17]. Other recent studies with
different dosages and study designs have not demon-
strated that circulatory PS levels associate with risk of
CVD and hence, consumption of portfolio diet contain-
ing PS may be safe and reduce risk of CVD [18-22].
Cholesterol lowering effects induced by the portfolio
diet could occur through mechanisms including reduced
intestinal cholesterol absorption due to PS [23], decreased
cholesterol synthesis and elevated LDL-C receptor uptake
of cholesterol in liver by soy proteins [24] increased bile
acid loss by the action of dietary fibre [25] and almonds
are sources of vegetable proteins, monounsaturated fats
and PS and are likely to produce their effects by a range of
mechanisms [26]. As PS act mainly by inhibiting intestinal
cholesterol absorption, it might be possible that the
absorption of other fat soluble compounds such as
carotenoids, tocopherols and retinoids are compromised
by the PS containing portfolio diet consumption [27].
Vitamin A is essential for multiple functions in the
human body including maintenance of cell function,
growth, vision, epithelial integrity, immune function,
and reproduction. Deficiency of vitamin A leads to
vision loss, increased morbidity, and mortality [28,29].
Tocopherols are strong antioxidants and play important
role in prevention of chronic diseases associated with
oxidative stress such as cardiovascular disease, athero-
sclerosis, and cancer [30]. Deficiency of vitamin E leads
to anemia and in addition severe deficiency could result
in neuromuscular abnormalities characterized by spino-
cerebellar ataxia and myopathies [30-32].
A few studies have raised concerns about reduction in
the absorption of fat soluble vitamins and carotenoidsincluding β-carotenes and α-tocopherols following PS
intake [33-38]. In contrast, other interventions have
shown no changes in plasma fat soluble vitamin
concentrations with PS consumption [39-42]. Although
combination of PS with other portfolio dietary compo-
nents showed significant reductions in plasma LDL-C
concentrations, effects of portfolio ingredients on
plasma fat soluble vitamins levels have never been
studied. Hence our aim was to determine whether the
portfolio diet with the presence of PS affects the plasma
fat soluble vitamin concentrations in hypercholesterolemic
participants. Additional objectives were to determine the
extent of the increment in plasma PS concentration
following a portfolio diet and determine the correlations
with other lipid markers in blood.
Participants and methods
Participants
We have previously reported the results on the effect of
portfolio diet on CVD risk factors including plasma
LDL-C levels [4]. Detailed information on the study
design and participant characteristics of this multi-centre
clinical study has been provided [4]. Briefly, 351 hyperlip-
idemic participants (137 males and 214 postmenopausal
females) were randomized for the study at 4 different
centers across Canada including Quebec City, Toronto,
Winnipeg and Vancouver. The main inclusion criteria
were males and post-menopausal females with low to
intermediate Framingham 10-year risk categories with
3.50-5.31 and 3.00-4.61 mmol/L LDL-C respectively.
The following were considered as exclusion criteria;
history of cardiovascular disease, cancer or strong family
history of cancer, untreated hypertension with blood
pressure >140/90 mmHg, diabetes, hepatic or renal
disease and currently under lipid lowering therapy. The
trial is registered in clinical trials.gov registry (Identifier:
NCT00438425).
Study protocol
Participants were recruited by advertisements. The study
protocol was explained to all participants and signatures
on informed consent forms were obtained from eligible
participants. Eligible participants were randomized in
blocks of 75 participants with stratification by centre,
gender and baseline LDL-C concentrations with greater
than or lesser than 4.09 mmol/L. In this study with a
parallel design, participants were randomized to one of
the three treatment groups with either a therapeutic low
fat diet control or dietary portfolio of cholesterol lowering
foods with either 2 visits (routine) or 7 visits (intensive)
during a 6 month period (Figure 1). Participants visited
the respective centers at baseline and by 3 and 6 months
for the control and portfolio routine diet groups. Partic-
ipants categorized to intensive dietary portfolio group
Figure 1 Schematic representation of the study protocol. *Indicates visit to the centre; collection of 7-day diet record/check lists, satiety score;
body weight and blood pressure measurement and fasting blood collection.
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subsequently every month. During each of the visits, the
preceding 7-day dietary histories were collected and
reviewed along with recording the body weight and
blood pressure. Fasting blood samples were collected
from the participants during each visit. Serum lipid
profile and apolipoproteins were measured as explained
earlier [4]. This study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures were approved by the ethics committees
of Universities of British Columbia, Laval, Manitoba
and Toronto as well as St Michael’s Hospital, Toronto.
Diets consumed by the participants were previously
explained in detail [4]. During the 6 month study treat-
ment period, participants received dietary advice by
dieticians to follow a weight maintaining vegetarian diets
with foods available at supermarkets and health food
stores. Participants in the dietary portfolio groups were
recommended to incorporate the portfolio dietary study
foods into their diets. The aim was to provide 0.94 g of
PS in margarine, 9.8 g of viscous fibre, 22.5 g of soy
proteins and 22.5 g of nuts per 1000 kcal of diet per day.
Control dietary participants were advised to consume low
fat dairy and whole grain cereals along with fruits and vege-
tables and to avoid the portfolio dietary components. All
participants were supplied with measuring cups and spoons
to control the amount of portfolio and control dietary foods
consumption. Diets were analyzed using a program based
on US Department of Agriculture data (ESHA Food Pro-
cessor SQL version 10.1.1; ESHA, Salem, Oregon).
Concentrations of plasma α and γ tocopherols, β-
carotene, lutein, lycopene and retinol were measured con-
currently with an isocratic high performance liquid chro-
matograph (HPLC) (1100 HPLC, Agilent Technologies,
Palo Alto, California) as described earlier [43]. Briefly, in-
ternal standards retinol acetate and β-apo-8′-carotenal in
methanol were added to each of the samples and deprotei-
nized with ethanol followed by extraction with hexane.
Samples were injected into a C18 reverse phase column
(Zorbax Eclipse XBD, Agilent Technologies, Palo Alto,
California) with a guard column and eluted with mobile
phase consisting of methanol, acetonitrile and tetrahydro-
furan in the ratio of 75:20:5 (v/v/v). Detection wavelengthswere set at 290, 320 and 450 nm for detection of the com-
pounds of interest. Fat-soluble vitamins were identified
using authentic standards (Sigma-Aldrich) and were quan-
tified using standard curves.
Concentrations of PS in plasma were measured by
gas chromatography (6890 GC, Agilent Technologies,
Palo Alto, California) equipped with a flame ionization
detector and auto-injector system. A 30-m SAC-5 col-
umn (Sigma-Aldrich Canada Ltd., Oakville, Ont.) was
used. Briefly, 5-α cholestane as an internal standard
was added to each of the samples followed by addition
of methanolic potassium hydroxide and saponification.
Sterols were extracted from the mixture with petrol-
eum ether. Extracted samples were derivatized with
TMS reagent (pyridine-hexamethyldisilazane-trimethyl-
chlorosilane (9:3:1, v/v)) and samples were injected
into the GC [44]. The injector and detector were set
at 300 and 310 degrees C, respectively. The flow rate
of the carrier gas, helium was 1.2 ml/min with the in-
let splitter set at 100:1. Individual PS were identified
using authentic standards (Sigma-Aldrich Canada Ltd.,
Oakville, Ont). Internal standards were used to calcu-
late detector response factors. Campesterol and β-
sitosterol concentrations were determined by identify-
ing the peak sizes and expressing them relative to 5-α
cholestane internal standard. As PS and fat soluble vi-
tamins are mainly transported in cholesterol-containing
particles in serum, the absolute concentrations were ad-
justed for the serum cholesterol concentration to elimin-
ate the effect of changes in the serum cholesterol
concentration.
Statistical analyses
Data are expressed as means with their standard errors.
The significance of the differences between week 0, week
12 as well as week 24 between different groups were
assessed by Least Squares Means utilizing PROC MIXED
procedure in SAS, with Tukey adjustment for multiplicity
of comparisons. Analysis of covariance was performed
with sex, treatment, centre and centre-by-treatment
interaction as main effects and baseline as a covariate. In
all tests of hypotheses, p values <0.05 were considered
significant. All statistical analyses were performed using
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NC, USA) Sample size determination with LDL-C as
primary end point has been explained in detail earlier [4].
Results
Baseline characteristics of participants and dietary intakes
during the study
Baseline characteristics of participants of all treatments
were similar except for the relatively higher ratio of men
to women on the intensive portfolio group compared to
the other groups (Table 1). Adherence to the dietary
recommendations assessed from the 7 day food records
using food processor software was 46.4% and 40.6% for
the intensive and routine portfolio diets, respectively [4].
Dietary macronutrient profile of the portfolio and
control diets were explained in Table 2. Participants in
intensive and routine portfolio groups consumed 0.8
and 0.6 g/d/1000 Kcal PS in their diets, respectively.
The amount of vitamin A consumed during the study
by participants in intensive and routine portfolio
dietary groups was 1280 and 1248 IU compared with
control group which was 1699 IU per day. In contrast,
intakes of vitamin E were higher with participants in
intensive (3.0 IU/d) and routine (2.8 IU/d) portfolio
groups compared to the control dietary group (1.6 IU/d).Table 1 Baseline characteristics of participants
Characteristic
Portfolio intensive (n = 101)




Body weight, mean (SD), kg 75.5 (13.5)
Body mass index, mean (SD), kg/m2 26.6 (4.0)
Blood pressure, mean (SD), mm Hg
Systolic 120.9 (12.6)
Diastolic 73.1 (9.0)






Lipid lowering medication 13 (12.9%)
Antihypertensive medication 18 (17.8%)
Hormone-replacement medication 2 (2%)
Thyroxine 9 (8.9%)
ap-values calculated by ANOVA for continuous variables.
bp-values calculated by CHI2/Fisher’s Exact Test for categorical variables.
cMean lipid levels for 100 subjects in the portfolio intensive group, for 122 subjectsSerum lipid profile changes with portfolio and control
diets
Reductions in serum total and LDL-C level with
consumption of portfolio diets are reported in Table 3
[4]. No differences were found between the 3 interven-
tion groups in baseline blood lipid concentrations.
Percentage change and absolute treatment differences
between the control and the two dietary portfolio
interventions were significant for LDL-C (p < 0.001) and
in absolute units for the TC:HDL-C ratio (intensive dietary
portfolio: p = 0.004, routine dietary portfolio: p = 0.006),
with no significant differences seen between the two
dietary portfolio groups (p = 0.66).
Effect of portfolio diet on plasma fat soluble compound
concentrations
Plasma concentrations of tocopherols, carotenoids and
retinol and their ratios to cholesterol are shown in
Table 4. Participants consuming the intensive portfolio
diet showed no changes in any of the fat soluble vitamins
measured except for a slight but significant increase in
cholesterol adjusted α-tocopherol (p = 0.014) and retinol
(p = 0.032) at week 12, but not at week 24. Furthermore,
concentrations of β-carotene and retinol were found to be
decreased with intensive portfolio diet only at week 24Treatments P-valuea, b
Portfolio routine (n = 122) Control (n = 122)
57.1 (8.3) 56.9 (9.3) 0.082
37 (30.3%) 47 (38.5%) 0.014
85 (69.7%) 75 (61.5%)
73.7 (13.3) 76.9 (13.8) 0.189
26.9 (3.8) 27.4 (3.9) 0.244
119.5 (13.5) 119.9 (11.9) 0.683
73.8 (8.3) 73.0 (8.0) 0.731
6.63 (1.06) 6.45 (0.87) 0.830
4.50 (0.88) 4.35 (0.72) 0.380
1.40 (0.40) 1.39 (0.36) 0.836
1.61 (0.83) 1.65 (0.98) 0.574
20 (16.4%) 18 (14.8%) 0.754
17 (13.9%) 28 (23.0%) 0.193
7 (5.7%) 2 (1.6%) 0.195
11 (9%) 15 (12.3%) 0.627
in the portfolio routine, and for 121 subjects in the control.







Energy, Kcal/d 1977 1804 1802
Total protein 88(18) 79(18) 80(18)
Available carbohydrate 225(45) 208(46) 225(50)
Total dietary fibre (g/100 kcal) 42(22) 36(20) 31(17)
Total fat 70(32) 63(31) 52(26)
Saturated fatty acid 14(7) 14(7) 14(7)
Monounsaturated fatty acid 27(12) 24(12) 19(9)
Polyunsaturated fatty acid 18(9) 16(8) 11(6)
Cholesterol (mg/1000 kcal) 123(66) 120(68) 154(86)
Data are expressed as mean grams per day (% energy intake) unless stated and based on the dietary data obtained at week 24 of the study.
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changes in any fat soluble vitamin concentrations were
noted in routine portfolio diet group, except for an
increase in cholesterol adjusted γ-tocopherol at week 12
(p = 0.003), as well as at week 24 (p = 0.014) and
decreased β-carotene (p = 0.016) and α-tocopherol
(p = 0.041) only at week 12, but not at week 24. Con-
sumption of the control diet had no impact on plasma
vitamin concentrations except for an increase in chol-
esterol adjusted β-carotene at week 12 (p = 0.018) but
not at week 24.
No differences between the three dietary interven-
tions were observed with changes from respective base-
lines of any of fat soluble vitamins measured except for
a significant reduction in concentration of β-carotene at
week 12 with intensive (p = 0.045) and routine (p = 0.031)
portfolio diet, compared to changes with control diet. How-
ever, the change from baseline in β-carotene concentration
at week 24 with routine portfolio diet group was not
different (p = 0.078) when compared to change with
control diet group, but was lower with >intensive port-
folio diet (p = 0.039) compared to changes from base-
lines observed in control dietary group. Furthermore,
cholesterol adjusted concentrations of fat soluble vita-
mins, especially β-carotene, were not different across
intervention groups. Changes in cholesterol adjusted
concentrations of plasma fat soluble compounds with
portfolio diet consumption were negatively correlated with
changes in total cholesterol (α-tocopherol: p = 0.005;
retinol: p = 0.008; lutein: p = 0.031; lycopene: p = 0.004; β-
carotene: p = 0.009) and LDL-C (α-tocopherol: p = 0.004;
retinol: p = 0.004; lutein: p = 0.027; lycopene: p = 0.004;
β-carotene: p = 0.013) levels (Table 5). Furthermore,
changes in cholesterol adjusted plasma concentrations
of α-tocopherol (p = 0.026), retinol (p = 0.038) and lycopene
(p = 0.048) showed a negative correlation with serum apoB
concentrations.Changes in plasma plant sterol concentrations during the
study
Plasma PS concentrations including campesterol and
β-sitosterol and their ratio with cholesterol are depicted
in Figure 2. The intensive portfolio diet group showed
an increase in concentration of campesterol at week 24
(p = 0.034) compared with baseline. Similarly, partici-
pants consuming the routine portfolio dietary group
also demonstrated increased campesterol concentra-
tions at both weeks 12 (p < 0.001) and 24 (p < 0.001),
respectively, compared to baseline. Ratios of campes-
terol and cholesterol were also found to be increased
by intensive (p = 0.001 at week 12, p < 0.001at week 24)
as well as routine (p < 0.001 at week 12 and 24) portfolio
diet consumption. No significant changes in campesterol
and cholesterol-adjusted campesterol concentrations were
observed after consuming the control diet. Plasma con-
centrations of β-sitosterol were found to be increased in
both intensive (p = 0.008 at week 12, p < 0.001 at week 24)
and routine (p < 0.001 at week 12 and 24) portfolio diet
groups. Increases in cholesterol adjusted β-sitosterol
concentrations in plasma were similarly elevated as
unadjusted β-sitosterol concentrations (p < 0.001) at
week 12 and 24 after intensive or routine portfolio diet
consumptions compared to their baselines. Concentra-
tions of β-sitosterol and its ratio to cholesterol were
significantly elevated in participants consuming control
diet at 12 weeks (β-sitosterol: p = 0.024; ratio to choles-
terol p = 0.032) as well as at 24 weeks (p = 0.05).
No differences across time were observed across par-
ticipants consuming intensive and routine portfolio
diet in circulating campesterol and β-sitosterol levels,
or their ratios to cholesterol. However, increased plasma
campesterol and β-sitosterol concentrations were ob-
served with both intensive (week 24: p = 0.012 for campes-
terol and p = 0.035 for β-sitosterol) as well as routine
(week 24: p = 0.034 for campesterol and p = 0.080 for β-
Table 3 Effect of portfolio and control diets on blood lipids levels and the differences between dietary interventions
Treatmentsa Between treatment differencesb
Variable Portfolio intensive (n = 101) Portfolio routine (n = 122) Control (n = 122) PI vs. PR PI vs. C PR vs. C
Wk 0 Wk 24 Wk 0 Wk 24 Wk 0 Wk 24 Mean (95% CI) P-value Mean (95% CI) P-value Mean (95% CI) P-value
Cholesterol, mmol/L
Total 6.53 5.88 6.63 6.04 6.46 6.41 −0.07 (−0.31, 0.17) 0.777 −0.56 (−0.80, −0.33) <0.0001 −0.49 (−0.73, −0.26) <0.0001
LDL-C 4.42 3.80 4.50 3.92 4.35 4.24 −0.06 (−0.27, 0.15) 0.773 −0.46 (−0.67, −0.26) <0.0001 −0.40 (−0.60, −0.20) <0.0001
HDL-C 1.42 1.39 1.40 1.39 1.39 1.40 0.007 (−0.006, 0.072) 0.965 −0.02 (−0.09, 0.04) 0.619 −0.03 (−0.09, 0.03) 0.453
Triglycerides 1.52 1.50 1.61 1.60 1.66 1.72 −0.06 (−0.23, 0.12) 0.743 −0.10 (−0.27, 0.07) 0.372 −0.04 (−0.21, 0.13) 0.824
Total:HDL-C 4.81 4.44 5.01 4.60 4.93 4.87 −0.05 (−0.27, 0.17) 0.852 −0.33 (−0.54, −0.11) 0.001 −0.28 (−0.50, −0.06) 0.008
Apolipoproteins g/L
A1 1.60 1.60 1.60 1.60 1.60 1.59 0.02 (−0.02, 0.06) 0.533 0.01 (−0.03, 0.05) 0.868 −0.01 (−0.05, 0.03) 0.819
B 1.23 1.10 1.26 1.14 1.20 1.20 −0.01 (−0.06, 0.03) 0.846 −0.11 (−0.16, −0.07) <0.0001 −0.10 (−0.15, −0.06) <0.0001
aFor paired samples T-test of change from baseline, done on absolute change values.
bUsing analysis of covariance with sex, treatment and sex by treatment interaction as main effects and baseline as a covariate. A Tukey adjustment was made for multiple comparisons. Abbreviations: PI Portfolio
















Table 4 Plasma concentrations of carotenoids, tocopherols and retinoids following portfolio and control diets
Variable Intensive portfolio Routine portfolio Control
Wk 0 Wk 12a Wk 24a Wk 0 Wk 12a Wk 24a Wk 0 Wk 12a Wk 24a
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
α-tocopherolb 47.72 2.51 45.60 2.71 45.23* 2.55 50.15 2.37 47.36* 2.77 47.50 2.83 51.05 2.71 51.76 2.99 49.72 3.05
γ-tocopherolb 4.97 0.22 4.76 0.29 4.71 0.29 5.28 0.30 5.10 0.35 4.99 0.36 4.96 0.30 5.22 0.37 5.21 0.35
Lycopeneb 2.61 0.13 2.49 0.23 2.49 0.13 2.78 0.20 2.53 0.17 2.56 0.17 3.21 0.20 3.23 0.17 3.06 0.23
Luteinb 1.65 0.19 1.51 0.21 1.64 0.21 1.80 0.17 1.67 0.16 1.80 0.18 1.71 0.15 1.77 0.18 1.69 0.19
β-caroteneb 2.24 0.19 2.07† 0.18 2.06*† 0.19 2.27 0.17 2.11*† 0.17 2.20† 0.17 2.23 0.18 2.38 0.18 2.45 0.17
Retinolb 2.78 0.12 2.65 0.16 2.65* 0.15 2.94 0.15 2.88 0.13 2.83 0.15 2.73 0.12 2.86 0.15 2.84 0.19
α-tocopherol:TCc 7.46 0.46 8.39* 0.51 8.00 0.49 7.91 0.46 8.41 0.55 8.25 0.49 8.07 0.53 8.54 0.53 8.04 0.51
γ-tocopherol:TCc 0.79 0.04 0.88 0.05 0.81 0.05 0.80 0.05 0.91* 0.07 0.88* 0.07 0.81 0.06 0.86 0.06 0.83 0.05
Lycopene:TCc 0.42 0.02 0.45 0.04 0.44 0.02 0.42 0.04 0.44 0.03 0.45 0.03 0.50 0.04 0.54 0.03 0.49 0.04
Lutein:TCc 0.29 0.04 0.29 0.04 0.30 0.04 0.29 0.03 0.31 0.03 0.32 0.03 0.28 0.03 0.29 0.03 0.28 0.03
β-carotene:TCc 0.35 0.04 0.38 0.03 0.37 0.04 0.36 0.03 0.38 0.03 0.38 0.03 0.35 0.03 0.40* 0.03 0.39 0.03
Retinol:TCc 0.43 0.02 0.49* 0.03 0.47 0.03 0.47 0.03 0.52 0.03 0.50 0.03 0.43 0.02 0.47 0.03 0.46 0.03
*Indicates significance compared to respective baseline. †indicates significance with changes from baseline compared to control at respective time point.
aUsing analysis of covariance with sex, treatment and sex by treatment interaction as main effects and baseline as a covariate. A Tukey adjustment was made for
multiple comparisons. bμmol/L. cμmol/L:mmol/L.
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diet. Plasma campesterol and β-sitosterol concentrations
after adjusting for blood cholesterol concentrations were
also found to be elevated after consumption of intensive
(week 12: p = 0.037 for campesterol:TC and p = 0.022 for
β-sitosterol:TC; week 24: p = 0.001 for campesterol:TC
and p = 0.002 for β-sitosterol:TC) and routine (week 12:
p = 0.054 for β-sitosterol:TC; week 24: p = 0.003 for cam-
pesterol:TC and p = 0.002 for β-sitosterol:TC) portfolio
diets, compared with consumption of the control diet.
Changes in plasma campesterol:TC ratio with portfolio
diet were found to be negatively correlated with total
(p = 0.0001) and LDL-C (p = 0.0004), as well as with
apoA1 (p = 0.001) and ApoB (p = 0.002) levels and LDL-
C/ApoB ratio (p = 0.009) (Table 6). Similarly, changes in
plasma β-sitosterol:TC ratios after consuming portfolio
diets were also observed to be negatively correlated withTable 5 Correlations between changes in plasma carotenoid,
markers after consumption of portfolio
Variable γ-tocopherol:TC α-tocopherol:TC
TC N 161 161
r −0.111 −0.219
P 0.161 0.005
LDL-C N 160 160
r −0.088 −0.225
P 0.271 0.004
ApoB N 161 161
r −0.073 −0.175
P 0.360 0.026the change in total (p = 0.0002) and LDL-C (p = 0.0001) and
ApoB (p = 0.0004) levels, as well as in cholesterol:HDL-C
ratio (p = 0.021), LDL-C:HDL-C ratio (p = 0.010), apoB:
apoA1 ratio (p = 0.001) and LDL-C:apoB ratio (p = 0.036).
Discussion
Results demonstrate that intake of a portfolio diet for
6 months improved blood lipid concentrations without
altering the plasma fat soluble vitamin concentrations
after adjustment for cholesterol levels. Phytosterol intake
has been believed to result in a possible reduction in
absorption of fat soluble vitamins which in turn might
lead to their lower levels in plasma [33,34,37]. Caroten-
oids, retinols and tocopherols are absorbed in the intestine
in a similar fashion to lipids. PS lower blood cholesterol by
inhibiting cholesterol absorption in the gut. Hence, the
possibility exists that consumption of PS might reducetocopherol and retinoid concentrations with lipid
Retinol:TC Lutein:TC Lycopene:TC β-carotene:TC
161 159 157 156
−0.209 −0.171 −0.230 −0.209
0.008 0.031 0.004 0.009
160 158 156 155
−0.228 −0.176 −0.229 −0.200
0.004 0.027 0.004 0.013
161 159 157 156
−0.163 −0.138 −0.158 −0.129
0.038 0.083 0.048 0.110
Figure 2 Plasma concentrations of plant sterols and their ratios with cholesterol after consumption of portfolio and control diets. a.
Campesterol, b. β-sitosterol, c. campesterol:TC, d. β-sitosterol:TC. *Indicates significance compared to respective baseline. †indicates significance
with changes from baseline compared to control at respective time point. bindicates significance with changes from baseline compared to routine
portfolio at respective time point. Using analysis of covariance with sex, treatment and sex by treatment interaction as main effects and baseline as a
covariate. A Tukey adjustment was made for multiple comparisons.
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http://www.nutritionj.com/content/13/1/101circulating concentrations of these fat soluble com-
pounds due to their reduced intestinal absorption [27].
Reductions in serum carotenoids and lycopene con-
centrations in normocholesterolemic and mildly hyper-
cholesterolemic participants were observed with PS
consumption [27,35,36,45,46]. Reductions in plasma
fat soluble compounds concentrations found in these
interventions might be because of their lower absorp-
tion or due to reduced lipoprotein carriers and serum
cholesterol concentrations. However, when concentra-
tions of these fat soluble compounds were corrected
for plasma lipid levels, only carotene concentrations
were shown to be reduced in some trials [27,35]. In the
current intervention, no such reductions occurred in
any of the measured plasma fat soluble compound
levels across intervention groups suggesting that other
components of the portfolio diet might have compensated
for the effect of PS on fat soluble vitamins. Vitamins A
and E are essential to maintain normal health and immune
system and their deficiency lead to chronic diseases
[28,31]. Consumption of portfolio diet did not affect the
plasma concentration of these vitamins which indicates
the safety with the portfolio diet with absorption of fat
soluble compounds.
Results from current intervention showed no changes
across the three dietary groups in plasma concentrations
of tocopherols, retinoids and carotenoids, except for adecrease in β-carotene with portfolio groups compared
to the control diet group. However, the cholesterol
adjusted β-carotene concentrations in plasma showed no
differences across all the groups. These findings indicate
that consumption of a portfolio diet reduces blood chol-
esterol but does not affect the absorption of fat soluble
vitamins. No changes in cholesterol adjusted fat soluble
vitamins concentrations with portfolio diet consumption
also indicate that decreased plasma carotenoid concen-
trations reflect reductions in carrier lipoproteins,
especially LDL-C. Results of earlier studies are variable
ranging from no change in any of the fat soluble com-
pounds in serum [39,41,47,48] to considerable changes
[38] or differences only in β-carotene [49-51]. The lack
of consistency in results might be due to different
background diets during the intervention and eating
habits of the participants. In most of the interventions,
diets are not strictly controlled and supervised by
study investigators. In contrast, well-controlled human
trials with strictly controlled diets have shown no
significant differences in concentrations of circulating
fat soluble compounds [40,48].
In the current trial, participants in intensive and
routine portfolio diet groups consumed significantly
higher amounts of vitamin E compared to participants
consuming the control diet, which might also be a
reason for not finding any reduction in plasma vitamin E
Table 6 Correlations between changes in plasma plant
sterol concentrations and lipid markers with portfolio
diet consumption
Variable Campesterol:TC β-sitosterol:TC
TC N 156 152
R −0.302 −0.294
P 0.0001 0.0002
LDL-C N 155 151
R −0.281 −0.307
P 0.0004 0.0001
ApoA1 N 156 152
R −0.269 −0.019
P 0.001 0.815
ApoB N 156 152
R −0.242 −0.285
P 0.002 0.0004
TC/HDL-C N 155 151
R −0.008 −0.188
P 0.921 0.021
LDL-C/HDL-C N 155 151
R −0.046 −0.209
P 0.568 0.010
ApoB/ApoA1 N 156 152
R −0.056 −0.265
P 0.488 0.001
LDL-C/ApoB N 154 150
R −0.211 −0.172
P 0.009 0.036
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http://www.nutritionj.com/content/13/1/101concentrations after consuming portfolio diet. The
amount of vitamin A consumption was not signifi-
cantly different with portfolio dietary groups compared
to respective baselines. However, dietary intake of
vitamin A by participants in control group was signifi-
cantly higher than that of the portfolio group which
could have contributed to the increase observed in
plasma vitamin A concentrations after the control diet
intake, compared with the portfolio dietary groups.
Several investigators recommended consumption of
carotenoid rich foods including fruits and vegetables
along with PS consumption to prevent reductions in
fat soluble compound levels [12,51,52]. PS did not
affect the β-carotene absorption in participants with
mild hypercholesterolemia when consumed PS esteri-
fied to fish oil, but not to sunflower oil [47]. Earlier
studies have also shown that PS consumption when
distributed over the day results in an optimal choles-
terol lowering effect rather than a single large dose
[6,53]. Hence, the background diet and feeding strategyplay important roles in terms of effects of PS consumption
on plasma concentrations of fat soluble compounds.
Plasma concentrations of retinol and tocopherols were
consistent with the ranges seen in our previous publica-
tions [47,48,54] as well as Sowell et al. [55]. Although
the plasma carotenoid concentrations in the current
study appear to be slightly higher than values observed
by other researchers [55], they were in the same range
as found earlier [48]. Plasma samples could be detected
with not only the compounds of interest for measure-
ment in the study but also other compounds such as
alpha-cryptoxanthin, cis-beta-carotene (13-cis), cislyco-
pene (at least three isomers), cis-lutein/zeaxanthin etc.
Presence of the compounds might lead to detection of
higher concentration of a given compound which also
depends on the relative concentrations of the analyte as
well as the interferent. Olmedilla et al. measured the
plasma retinol, tocopherol and carotenoid concentra-
tions in the Spanish population and compared their
concentrations with those of other country’s populations
[56]. Results indicated that carotenoid concentrations
showed differences from two to five fold in the reported
values. Variations might be due to differences between
population and seasonality.
Consumption of our PS containing diet resulted in
substantial increases in plasma concentrations of both
campesterol and β-sitosterol. Previous trials with humans
have shown that consumption of 1.8 g/day of PS increases
plasma campesterol and β-sitosterol concentrations from
9 to 16.6 and 4.4 to 6.0 μmol/ L respectively [57]. Results
from current work were consistent with the previous data
where consumption of portfolio diet consisting 2 g/d
of PS increased the plasma PS concentrations [58].
Supplementation of a larger dose of 6.6 g/day of PS led
to elevations in circulating campesterol and β-sitosterol
concentrations from 7.8 to 15.8 and 8.0 to 11.4 μmol/L
respectively [49]. In those trials, plasma PS concentrations
were considerably lower than those seen in homozygous
phytosterolemic patients who presented with levels of
290–966 μmol/L [17,59].
Some studies have suggested that moderately increased
concentrations of PS in plasma could be associated with
increased risk of CVD [13,14]. Glueck et al. and Assmann
et al. observed correlations between campesterol or
β-sitosterol alone and CVD risk, respectively [13,14].
However, these trials concluded that an association
exists between plasma PS concentrations and CVD
risk, but failed to find the correlations with CVD risk
independently from plasma cholesterol concentrations
which itself is a risk factor for CVD. A number of
investigations with different study designs have shown
that plasma PS levels have no association with the risk
of CVD [20-22,60-62]. Results of the current investiga-
tion showed significant negative correlations between
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http://www.nutritionj.com/content/13/1/101plasma PS concentrations and total and LDL-C, as well
as apoB. However, no significant correlation was found
between the Framingham risk score and plasma PS
concentrations in the present work. In a trial with 2542
middle aged humans, plasma PS concentrations failed
to be associated with increased risk of CVD [21]. Simi-
larly, the prospective EPIC-Norfolk population study
had failed to observe any differences in PS concentra-
tions in plasma of healthy participants who developed
CVD during the 6 year follow up when compared to
their case matched controls [20]. In the Longitudinal
Aging Study Amsterdam (LASA), with 1242 partici-
pants with 65 years of age, moderately increased con-
centrations of plasma PS were shown to be associated
with reduced CVD risk [19]. Based on these findings,
increased plasma PS concentrations due to consump-
tion of PS cannot be considered to be associated with
elevated CVD risk. It can be ventured that finite merit
exists in maintaining circulating PS levels in the upper
range of normal to minimize disease risk.
The study has some limitations as follows. Intake of
vitamin E levels during the study was higher with portfo-
lio diet compared with control. In addition, vitamin A
intake was higher with control compared to the two
portfolio diet groups. Due to the complex nature of the
dietary intervention, the vitamin intakes were not same
across all the groups. Portfolio diet consisted of combin-
ation of various food components and hence the
changes in lipids, sterols and vitamins cannot be attrib-
uted to one single component. The study was a free
living study and not metabolically well controlled by
providing all the foods to the participants and follow
more closer. Hence, the compliance during the study
was less than 50% and drop out rate was 22.6%. How-
ever, the aim of the study was to determine the effect of
the portfolio diet in real world conditions without much
metabolic control and so the drop out rates is as
expected. Health benefits could be more than found in
the study if the diet is followed more strictly.
In conclusion, consumption of a portfolio diet including
PS, viscous fibres, soy proteins and nuts for 6 months
reduced blood cholesterol levels without affecting fat soluble
vitamin levels. Consequently, the portfolio diet consumption
not only reduces serum LDL-C, but also counteracts effects
of PS in reducing plasma fat soluble vitamins. Hence,
consuming portfolio diet could be considered as one of
the best options to maintain normal blood lipid levels
and reduce risk of CVD without any adverse effects.
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